Samuel Anderson, MD
Endocrinology, Diabetes & Metabolism · Columbus, OHNPI 1902883135
Payments from drug & device makers
Across 1,383 payments — averaging $402.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$216K
- Novo Nordisk$137K
- Sanofi-aventis U.S. LLC$66K
- AstraZeneca$57K
- Boehringer Ingelheim$36K
- Amarin Pharma, Inc.$15K
- plus $31K from 51 others
What the payments were for
- Consulting fees$6,4251%
- Speaking & faculty fees$508,62291%
- Travel & lodging$23,1254%
- Food & beverage$18,0593%
- Education$2360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$157,748
- JARDIANCE$84,860
- RYBELSUS$59,224
- FARXIGA$53,070
- SOLIQUA 100/33$52,560
- Ozempic$41,438
- TOUJEO$17,503
- Tresiba$14,124
- Vascepa$14,083
- Repatha$7,321
- GVOKE PFS$5,348
- Xultophy 100/3.6$5,185
- CYCLOSET$5,050
- AFREZZA$2,904
- BYDUREON$2,150
- Minimed 630G$1,625
- iLet Bionic Pancreas$375
- DEXCOM G6 TRANSMITTER$330
- MINIMED 780G$328
- iLet Insulin Infusion Kit Inset$125
How this compares
$556,467 in reported general payments places this provider in the 95th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 402 | $728,855 |
| JardianceEmpagliflozin | 249 | $317,990 |
| TrulicityDulaglutide | 152 | $270,400 |
| MounjaroTirzepatide | 121 | $187,529 |
| Tresiba Flextouch U-200Insulin Degludec | 128 | $148,984 |
| TymlosAbaloparatide | 40 | $122,649 |
| Teriparatide | 30 | $121,665 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $83,852 |
| Humalog Kwikpen U-200Insulin Lispro | 23 | $77,587 |
| Tresiba Flextouch U-100Insulin Degludec | 121 | $65,377 |
| ProliaDenosumab | 35 | $60,915 |
| ForteoTeriparatide | 15 | $58,008 |
| VascepaIcosapent Ethyl | 63 | $55,623 |
| FarxigaDapagliflozin Propanediol | 46 | $50,827 |
| Repatha SureclickEvolocumab | 42 | $50,402 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $136,874 | $743,902424 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Forteo, Humalog | $215,640 | $535,103338 claims |
| Boehringer IngelheimJardiance | $35,633 | $317,990249 claims |
| Radius Health, Inc.Tymlos | $272 | $122,64940 claims |
| AmgenProlia | $8,431 | $60,91535 claims |
| AstraZenecaFarxiga | $56,722 | $50,82746 claims |
| AbbVieSynthroid | $405 | $33,911326 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $65,618 | $28,44515 claims |
| MerckJanuvia | $100 | $26,81222 claims |
| PfizerGenotropin | $160 | $16,99112 claims |
| Antares Pharma, Inc.Xyosted | $244 | $13,37312 claims |
| Amneal Pharmaceuticals LLCUnithroid | $269 | $5,207114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Columbus
- Elena ChristofidesColumbus$3.5M
- Steven IngColumbus$1.9M
- Kathleen DunganColumbus$1.4M
- Kyaw SoeColumbus$1.3M
- Kathleen WyneColumbus$510K
- Luma GhalibColumbus$180K
- Ravi DhawaleColumbus$175K
- Lawrence KirschnerColumbus$142K
- Laura RyanColumbus$126K
- Jennifer SiposColumbus$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.